Envarsus Xr

Vitiligo, Pyoderma Gangrenosum, Kidney Transplantation + 12 more

Treatment

3 FDA approvals

20 Active Studies for Envarsus Xr

Treatment for

Vitiligo

What is Envarsus Xr

TacrolimusThe Generic name of this drug

Treatment SummaryTacrolimus (also known as FK-506 or Fujimycin) is an immunosuppressive drug used to prevent organ rejection after transplantation. It can also be used topically to treat severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and vitiligo. Tacrolimus was discovered in 1984 in a Japanese soil sample containing the bacteria Streptomyces tsukubaensis. It works by binding to the FKBP-12 protein, which inhibits the activity of an enzyme called calcineurin, which in turn reduces the activity of the immune

Prografis the brand name

image of different drug pills on a surface

Envarsus Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Prograf

Tacrolimus

1994

138

Approved as Treatment by the FDA

Tacrolimus, also called Prograf, is approved by the FDA for 3 uses such as Kidney Transplantation and Kidney .

Kidney Transplantation

Kidney

Immunosuppressive Treatment

Effectiveness

How Envarsus Xr Affects PatientsTacrolimus works by blocking a protein (FKBP-12) in the body that helps activate T-Lymphocyte cells and the production of IL-2. This helps to reduce the rate of organ rejection when compared to cyclosporine. It is also used to treat eczema and other skin conditions, as it helps reduce inflammation in a similar way to steroids, although it is not as powerful. An important benefit is that it can be used directly on the face, while topical steroids cannot, as they can thin the skin on the face. On other parts of the body, topical steroids are usually the better choice

How Envarsus Xr works in the bodyThe exact way tacrolimus works to treat atopic dermatitis is unknown. Research has found that tacrolimus blocks T-lymphocyte activation by binding to a protein in cells and forming a complex. This complex stops the production of certain proteins that are involved in T-cell activation and the release of other proteins from skin cells. It also reduces the number of receptors on a type of cell found in the skin.

When to interrupt dosage

The endorsed portion of Envarsus Xr relies upon the determined condition, such as Vitiligo, Rejection; Transplant, Kidney and Pyoderma Gangrenosum. The measure of dosage is subject to the means of delivery (e.g. Capsule, gelatin coated - Oral or Topical) listed in the table beneath.

Condition

Dosage

Administration

Pyoderma Gangrenosum

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Psoriasis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Vitiligo

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Immunocompromised

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Liver

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Kidney

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Rheumatoid Arthritis

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Chronic Graft Versus Host Disease

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Oral Lichen Planus

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Immunosuppressive Treatment

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Kidney Transplantation

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Prophylaxis against heart transplant rejection

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Dermatitis, Atopic

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Lung

0.5 mg, , 1.0 mg, 5.0 mg, 0.001 mg/mg, 0.0003 mg/mg, 4.0 mg, 0.75 mg, 3.0 mg, 0.2 mg, 0.03 %, 0.1 %, 5.0 mg/mL, 5.0 mg/mg, 0.00003 mg/mg, 0.003 mg/mg

, Oral, Capsule, Capsule - Oral, Topical, Ointment - Topical, Ointment, Capsule, coated, extended release, Capsule, coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, extended release, Tablet, extended release - Oral, Intravenous, Solution - Intravenous, Solution, Capsule, extended release, Capsule, extended release - Oral, Granule, Granule - Oral, Cutaneous, Ointment - Cutaneous, Injection, solution, Injection, solution - Intravenous, Granule, for suspension, Granule, for suspension - Oral, Kit, Cream, Cream - Topical, Solution - Topical

Warnings

Envarsus Xr Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Tacrolimus may interact with Pulse Frequency

There are 20 known major drug interactions with Envarsus Xr.

Common Envarsus Xr Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Tacrolimus.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Tacrolimus.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Tacrolimus.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Tacrolimus.

Bacillus calmette-guerin substrain russian BCG-I live antigen

Major

The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Tacrolimus.

Envarsus Xr Toxicity & Overdose RiskTaking too much of this drug can cause serious side effects like vision problems, issues with the liver or kidneys, seizures, shaking, high blood pressure, low magnesium levels, diabetes, high potassium levels, itching, difficulty sleeping, and confusion. The lowest toxic dose in rats is 134-194 mg/kg.

image of a doctor in a lab doing drug, clinical research

Envarsus Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Envarsus Xr?

There are 147 active clinical trials analyzing the potential of Envarsus Xr to manage Oral Lichen Planus, Pyoderma Gangrenosum and refractory Rheumatoid Arthropathy.

Condition

Clinical Trials

Trial Phases

Rheumatoid Arthritis

61 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Vitiligo

18 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Prophylaxis against heart transplant rejection

0 Actively Recruiting

Lung

0 Actively Recruiting

Pyoderma Gangrenosum

4 Actively Recruiting

Phase 2, Early Phase 1, Phase 3

Psoriasis

0 Actively Recruiting

Chronic Graft Versus Host Disease

29 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Oral Lichen Planus

1 Actively Recruiting

Phase 2

Dermatitis, Atopic

0 Actively Recruiting

Kidney Transplantation

0 Actively Recruiting

Liver

0 Actively Recruiting

Immunosuppressive Treatment

0 Actively Recruiting

Immunocompromised

4 Actively Recruiting

Phase 3, Not Applicable, Phase 1

Dermatitis, Atopic

0 Actively Recruiting

Kidney

0 Actively Recruiting

Envarsus Xr Reviews: What are patients saying about Envarsus Xr?

4Patient Review

2/21/2020

Envarsus Xr for Prevent Kidney Transplant Rejection

I've been on this medication for two months and have experienced slight tremors.

3.7Patient Review

9/22/2016

Envarsus Xr for Prevent Kidney Transplant Rejection

I have unfortunately gained weight in my midsection since starting this medication.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about envarsus xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of ENVARSUS XR?

"If you experience any of the following side effects, tell your doctor or pharmacist immediately: shaking, headache, diarrhea, nausea/vomiting, upset stomach,ordon sleeping."

Answered by AI

What is the difference between tacrolimus and Envarsus?

"ENVARSUS XR has better control over the release and absorption of tacrolimus than any other tacrolimus formulation. The MeltDose® Technology used to create ENVARSUS XR is a proprietary process that results in a controlled release of tacrolimus over a 24 hour period. This once-daily formulation overcomes the negative characteristics of other tacrolimus formulations."

Answered by AI

What is ENVARSUS XR used for?

"ENVARSUS XR helps to prevent organ rejection by reducing the body's ability to reject transplanted organs. It is an immunosuppressant, which is a type of medicine that reduces the body's immune response."

Answered by AI

Is there a generic for Envarsus?

"There is no other tacrolimus medicine that can be used as a substitute for ENVARSUS XR. The dosage for ENVARSUS XR is different from other tacrolimus products, so if you have been prescribed this medicine, make sure it is the only tacrolimus medicine you are taking."

Answered by AI

Clinical Trials for Envarsus Xr

Image of University of Colorado in Aurora, United States.

SBT777101 for Rheumatoid Arthritis

This trial is testing a new treatment called SBT777101 for people with rheumatoid arthritis. The study will look at whether it is safe and how it affects the participants. The treatment will be

University of Colorado (+4 Sites)Mark Eisner, MDSonoma Biotherapeutics, Inc.

Image of Marvel Clinical Research in Huntington Beach, United States.

Placebo +2 More for Vitiligo

Huntington Beach, CA

This trial is studying a medication called ritlecitinib to see how safe and effective it is in treating non-segmental vitiligo, a skin disorder characterized by white patches on the skin

Marvel Clinical Research (+10 Sites)Pfizer CT.gov Call CenterPfizer

Image of University of Miami in Miami, United States.

Horizons Group for Quality of Life

This trial tests if a group therapy program can improve quality of life for people with GvHD.

University of MiamiLara Traeger, PhD

Image of UNC Dermatology and Skin Cancer Center in Chapel Hill, United States.

Baricitinib for Oral Lichen Planus

Chapel Hill, NC

This trial is testing baricitinib to evaluate its effectiveness & safety in treating Oral Lichen Planus & its impact on quality of life.

UNC Dermatology and Skin Cancer CenterDonna Culton, MD, PhDEli Lilly and Company

Have you considered Envarsus Xr clinical trials? We made a collection of clinical trials featuring Envarsus Xr, we think they might fit your search criteria.

Explore trials for Envarsus Xr

Image of Michigan Center for Research Company /ID# 260069 in Clarkston, United States.

Upadacitinib +1 More for Vitiligo

This trial will evaluate if the drug upadacitinib is safe and effective in treating vitiligo, a chronic autoimmune skin disease. 540 participants will be enrolled worldwide to receive either upadacitinib or a placebo in Period A, followed by upadacitinib in Period B.

Waitlist Available

Michigan Center for Research Company /ID# 260069 (+34 Sites)ABBVIE INC.AbbVie

Image of Research Site in Montréal, Canada.

AZD6912 Dose 1 for Rheumatoid Arthritis

Montréal, Canada

This trial will test the safety and effects of increasing doses of AZD6912 given as a single injection under the skin to healthy volunteers.

Research SiteAstraZeneca

Image of University of Alabama At Birmingham Hospital-Whitaker Clinic in Birmingham, United States.

Povorcitinib for Vitiligo

This trial tests a new drug to treat vitiligo, a skin disorder that causes discoloration.

University of Alabama At Birmingham Hospital-Whitaker Clinic (+36 Sites)Incyte Medical MonitorIncyte Corporation

Image of Cahaba Dermatology in Hoover, United States.

Povorcitinib for Vitiligo

This trial tests if a new drug is safe and effective to treat vitiligo, a skin condition.

Cahaba Dermatology (+41 Sites)Incyte Medical MonitorIncyte Corporation

Have you considered Envarsus Xr clinical trials? We made a collection of clinical trials featuring Envarsus Xr, we think they might fit your search criteria.

Explore trials for Envarsus Xr

Image of Clinuvel investigational site in Los Angeles, United States.

SCENESSE + NB-UVB Light for Vitiligo

Los Angeles, CA

This trial will investigate if a drug and light therapy are better than light therapy alone for treating vitiligo on the body and face.

Clinuvel investigational siteClinuvel, Inc.

Image of Icahn School of Medicine at Mount Sinai in New York, United States.

Spesolimab for Pyoderma Gangrenosum

This trial will study if spesolimab can help treat ulcers caused by pyoderma gangrenosum, an autoimmune skin condition, and how it affects the body's immune system.

Icahn School of Medicine at Mount SinaiSaakshi Khattri, MDBoehringer Ingelheim

Image of Anniston Medical Clinic in Anniston, United States.

Imvotamab for Rheumatoid Arthritis

This trial will test if a drug (imvotamab) is safe and tolerable in people with RA who have failed other treatments. Placebos will also be given.

No Cost For Treatment

Anniston Medical Clinic (+13 Sites)Rebecca KunderIGM Biosciences, Inc.

Image of Altoona Center For Clinical Research Site Number : 8400002 in Duncansville, United States.

SAR441566 for Rheumatoid Arthritis

Duncansville, PA

This trial is testing a new drug treatment for rheumatoid arthritis in adults not adequately controlled on methotrexate. It will include 8 visits over 12 wks to assess safety & efficacy.

Altoona Center For Clinical Research Site Number : 8400002 (+7 Sites)Clinical Sciences & OperationsSanofi

Have you considered Envarsus Xr clinical trials? We made a collection of clinical trials featuring Envarsus Xr, we think they might fit your search criteria.

Explore trials for Envarsus Xr

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security